Scientists used CRISPR to reactivate uricase, an enzyme humans lost millions of years ago. Restoring the gene in liver cells ...

NtRON Bio announced today, following its recent U.S. patent application related to colorectal cancer using the IMPA™ phage engineering technology, it has now completed the filing of two patents for a ...

Another major buy was in INTELLIA THERAPEUTICS INC (NASDAQ:NTLA), with ARK purchasing 191,705 shares for around $2.18 million through its ARKK ETF. Similar to CRISPR, INTELLIA has seen increased ...

Researchers demonstrate the active role methyl groups play in silencing genes, demonstrating the therapeutic potential of ...

There were more than 48,000 organ transplants in the U.S. in 2024, a 3.3% increase from 2023, according to Organ Procurement ...

Scientists at MD Anderson created PreCiSE, a CRISPR tool that maps genes controlling natural killer (NK) cells. Editing these ...

On the buying side, ARK’s most notable investment was in CRISPR Therapeutics AG (NASDAQ:CRSP), acquiring 188,879 shares with a total dollar value of $10,259,907. This purchase indicates a strong ...

5 latest biotechnology breakthroughs, from genome sequencing to microbiome manipulation, revolutionizing medicine, ...

Shares of CRISPR Therapeutics CRSP have rallied 41.4% in the past three months, driven by encouraging data from a study of ...

For decades, large stretches of human DNA were dismissed as "junk" and considered to serve no real purpose. In a new study ...

The results suggest that lung xenotransplantation could one day become an option, but they also point to how much more work ...

The ability to correct disease-causing genetic mistakes using genome editors holds great promise in medicine, but it is not ...